New Jersey: Glenmark Pharmaceuticals Inc., USA (Glenmark) is pleased to announce the launch1 of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark’s Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat®2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254].
According to IQVIA® sales data for the 12-month period ending April 2026, the Vimpat® Injection market3 achieved annual sales of approximately $15.2 million*.
Marc Kikuchi, President & Business Head, North America said, “The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.”
1Glenmark’s Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials is only approved for the indication(s) listed in Glenmark’s approved label.
3Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for the indications listed in Glenmark’s approved label and is not marketed for all RLD indications.
